We are pleased to invite our old friend, Scott Powell, EVP and Head of IR of VolitionRx Limited (NYSE AMERICAN: VNRX), to join us for an updated interview. Scott elaborated on the company’s recent clinical study results on cancer diagnosis . Besides, he talked about a recent capital raising of over 19 million, and new global reach targets in terms of market expansion. The company is transitioning from clinical to commercial stage, and look forward to delivering earnings for the shareholders over the coming years.
Volition will present at our upcoming GCFF 2023 Toronto Conference on Oct 21st.
Free Registration Here!
About VolitionRx Limited (NYSE AMERICAN: VNRX)
Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition’s research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market. For more information. please visit their website.
NAI500’s new CEO Interview series is a program where we invite CEOs and senior executives of exciting public companies to uncover great investment opportunities for every day investors. If you don’t want to miss out on the great opportunities that we bring, subscribe to our YouTube channel and other social media channels below!
Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.
